Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.72 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.67 |
| ▸ | SELP | P16109 | 1/20 | 0.58 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918073 | 1.00 | HMGCR (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL2201502 | 1.00 | HMGCR (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL4225757 | 1.00 | HMGCR (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL2180780 | 1.00 | HMGCR (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL4231623 | 1.00 | HMGCR (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL2181335 | 1.00 | HMGCR (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL3796753 | 0.96 | PTPN7 (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL4453291 | 0.96 | PTPN7 (0.72) | HMGCRPTPN7SELPSOAT1MEN1 | |
| SCHEMBL12477833 | 0.93 | HMGCR (0.86) | HMGCRPTPN7MEN1KMT2AKDM4E | |
| Tetradecanamide SCHEMBL12477585 | 0.93 | HMGCR (0.86) | HMGCRPTPN7MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129062-A2 | TARGETED POLYMERIZED NANOPARTICLES FOR CANCER TREATMENT | Children's Hospital Los Angeles (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015153805-A2 | TARGETED POLYMERIZED NANOPARTICLES FOR CANCER TREATMENT | CHILDREN'S HOSPITAL LOS ANGELES (US) | 2015-10-08 | — | — | WO | claimed |
| US-20040232073-A1 | Bulk separation of semiconducting and metallic single wall nanotubes | NATIONAL SCIENCE FOUNDATION | 2004-11-25 | — | — | US | claimed |
| WO-2004082794-A2 | BULK SEPARATION OF SEMICONDUCTING AND METALLIC SINGLE WALL NANOTUBES | UNIVERSITY OF CONNECTICUT (US) | 2004-09-30 | — | — | WO | claimed |
| US-8703092-B2 | Type separation of single-walled carbon nanotubes via two-phase liquid extraction | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110166043-A1 | BIOMARKER DETECTION-2 | ATERIS TECHNOLOGIES, LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110165693-A1 | Duration and Environmental Monitoring Compositions, Devices Methods for Preparation and Systems | SEGAN INDUSTRIES INC. | 2011-07-07 | — | — | US | disclosed |
| US-20100326891-A1 | SEPARATION OF CARBON NANOTUBE BUNDLES VIA INTERFACIAL TRAPPING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100166637-A1 | Type Separation of Single-Walled Carbon Nanotubes via Two-Phase Liquid Extraction | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2010014625-A2 | DURATION AND ENVIRONMENTAL MONITORING COMPOSITIONS, DEVICES METHODS FOR PREPARATION AND SYSTEMS | SEGAN INDUSTRIES, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029004-A1 | DURATION AND ENVIRONMENTAL MONITORING COMPOSITIONS, DEVICES METHODS FOR PREPARATION AND SYSTEMS | SEGAN INDUSTRIES INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009036354-A2 | SEPARATION OF CARBON NANOTUBE BUNDLES VIA INTERFACIAL TRAPPING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008057070-A2 | TYPE SEPARATION OF SINGLE-WALLED CARBON NANOTUBES VIA PHASE TRANSFER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20040232073-A1 | Bulk separation of semiconducting and metallic single wall nanotubes | NATIONAL SCIENCE FOUNDATION | 2004-11-25 | — | — | US | disclosed |
| WO-2004082794-A2 | BULK SEPARATION OF SEMICONDUCTING AND METALLIC SINGLE WALL NANOTUBES | UNIVERSITY OF CONNECTICUT (US) | 2004-09-30 | — | — | WO | disclosed |
| US-5510481-A | LANGMUIR-BLODGETT FILM | THE REGENTS, UNIVERSITY OF CALIFORNIA (US) | 1996-04-23 | — | — | US | disclosed |
| US-5415999-A | Fluorescent lipid polymer-macromolecular ligand compositions as detection element in ligand assays | BIOCIRCUITS CORPORATION (US) | 1995-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166043-A1 | BIOMARKER DETECTION-2 | CPB2, NAALAD2, PRSS2 | HMGCR 1076/4885PTPN7 2138/4885SELP 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.